Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 18/20 | 0.52 |
| ▸ | ITGAV | P06756 | 18/20 | 0.52 |
| ▸ | ITGB1 | P05556 | 4/20 | 0.52 |
| ▸ | ITGB6 | P18564 | 4/20 | 0.52 |
| ▸ | ITGB5 | P18084 | 3/20 | 0.52 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.48 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.47 |
| ▸ | EEF2K | O00418 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6772750 | 0.96 | ITGB3 (0.55) | ITGB3ITGAVITGB1ITGB6ITGB5 | |
| SCHEMBL6767615 | 0.93 | ITGB3 (0.49) | ITGB3ITGAVITGB1ITGB6ITGB5 | |
| SCHEMBL6768513 | 0.87 | ITGB3 (0.56) | ITGB3ITGAVITGB1ITGB6ITGB5 | |
| SCHEMBL6773294 | 0.86 | ITGB3 (0.52) | ITGB3ITGAVITGB1ITGB6ITGB5 | |
| SCHEMBL6771727 | 0.85 | ITGB1 (0.48) | ITGB3ITGAVITGB1ITGB6ITGB5 | |
| SCHEMBL6774218 | 0.83 | ITGB3 (0.47) | ITGB3ITGAVITGB1ITGB6ITGB5 | |
| SCHEMBL6801394 | 0.83 | ITGB3 (0.50) | ITGB3ITGAVITGB1ITGB6ITGB5 | |
| SCHEMBL6768527 | 0.83 | ITGB3 (0.52) | ITGB3ITGAVITGB1ITGB6ITGB5 | |
| SCHEMBL6769604 | 0.83 | ITGB3 (0.47) | ITGB3ITGAVITGB1ITGB6ITGB5 | |
| SCHEMBL6778668 | 0.82 | ITGB3 (0.47) | ITGB3ITGAVITGB1ITGB6ITGB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6833366-B1 | Dihydrostilbene alkanoic acid derivatives | PHARMACIA CORPORATION | 2004-12-21 | — | — | US | claimed |
| US-6720315-B2 | FOR INHIBITING BONE RESORPTION, PERIODONTAL DISEASE, OSTEOPOROSIS, HUMORAL HYPERCALCEMIA OF MALIGNANCY, PAGET'S DISEASE, TUMOR METASTASIS, SOLID TUMOR GROWTH, ANGIOGENESIS, MACULAR DEGENERATION AND DIABETIC RETINOPATHY RETINOPATHY | PHARMACIA CORPORATION | 2004-04-13 | — | — | US | claimed |
| EP-1289959-A1 | DIHYDROSTILBENE ALKANOIC ACID DERIVATIVES USEFUL AS VITRONECTIN ANTAGONISTS | Pharmacia Corporation (US) | 2003-03-12 | — | — | EP | claimed |
| US-20020099209-A1 | Dihydrostilbene alkanoic acid derivatives | PHARMACIA CORPORATION | 2002-07-25 | — | — | US | claimed |
| WO-2001096310-A1 | DIHYDROSTILBENE ALKANOIC ACID DERIVATIVES USEFUL AS VITRONECTIN ANTAGONISTS | PHARMACIA CORPORATION (US) | 2001-12-20 | — | — | WO | claimed |
| US-6833366-B1 | Dihydrostilbene alkanoic acid derivatives | PHARMACIA CORPORATION | 2004-12-21 | — | — | US | disclosed |
| EP-1289959-A1 | DIHYDROSTILBENE ALKANOIC ACID DERIVATIVES USEFUL AS VITRONECTIN ANTAGONISTS | Pharmacia Corporation (US) | 2003-03-12 | — | — | EP | disclosed |
| WO-2001096310-A1 | DIHYDROSTILBENE ALKANOIC ACID DERIVATIVES USEFUL AS VITRONECTIN ANTAGONISTS | PHARMACIA CORPORATION (US) | 2001-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020099209-A1 | Dihydrostilbene alkanoic acid derivatives | ITGA5, ITGB5, ITGB1 | ITGB3 5/4885ITGAV 12/4885ITGB1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.